LIVZON PHARMA (01513) plans to spend 600 million to 1 billion yuan to repurchase A-shares.

LIVZON PHARMA (01513) announced that the company plans to repurchase a portion of its RMB ordinary shares (A shares) through centralized competitive bidding using its own funds or self-raised funds, for the purpose of cancelling and reducing registered capital. The total repurchase amount will be no less than RMB 600 million (inclusive) and no more than RMB 1 billion (inclusive), with a repurchase price not exceeding RMB 45.00 per share (inclusive). The specific number of repurchased shares will be based on the actual number of shares repurchased at the end of the repurchase period, which will not exceed 12 months from the date of approval of the share repurchase plan by the shareholders' meeting. In order to enhance the long-term investment value of the company's stock, protect the interests of investors, and enhance investor confidence, the company will repurchase a portion of its A shares through centralized competitive bidding using its own funds or self-raised funds. The repurchased shares will be cancelled and the registered capital will be reduced, in accordance with relevant provisions of laws, regulations, and normative documents such as the Company Law, Securities Law, Stock Repurchase Rules of Listed Companies, and Shenzhen Stock Exchange's Self-Regulatory Guidance No. 9 on Share Repurchase.